Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer

Marco Trovo, Emilio Minatel, Elena Durofil, Jerry Polesel, Michele Avanzo, Tania Baresic, Alessandra Bearz, Alessandro Del Conte, Giovanni Franchin, Carlo Gobitti, Imad Abu Rumeileh, Mauro G. Trovo

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Purpose To retrospectively assess toxicity and outcome of re-irradiation with stereotactic body radiation therapy (SBRT) in patients with recurrent or persistent non-small cell lung cancer (NSCLC), who were previously treated with radical radiation therapy (50-60 Gy). The secondary endpoint was to investigate whether there are dosimetric parameter predictors of severe radiation toxicity. Methods and Materials The analysis was conducted in 17 patients with "in-field" recurrent/persistent centrally located NSCLC, who underwent re-irradiation with SBRT. SBRT consisted of 30 Gy in 5 to 6 fractions; these prescriptions would be equivalent for the tumor to 37.5 to 40 Gy, bringing the total 2-Gy-per-fraction cumulative dose to 87 to 100 Gy, considering the primary radiation therapy treatment. Actuarial analyses and survival were calculated by the Kaplan-Meier method, and P values were estimated by the log-rank test, starting from the date of completion of SBRT. Dosimetric parameters from the subgroups with and without grade ≥3 pulmonary toxicity were compared using a 2-tailed Student t test. Results The median follow-up was 18 months (range, 4-57 months). Only 2 patients had local failure, corresponding to a local control rate of 86% at 1 year. The Kaplan-Meier estimates of overall survival (OS) rates at 1 and 2 years were 59% and 29%, respectively; the median OS was 19 months. Four patients (23%) experienced grade 3 radiation pneumonitis, and 1 patient developed fatal pneumonitis. One patient died of fatal hemoptysis 2 months after the completion of SBRT. Unexpectedly, heart maximum dose, D5 (minimum dose to at least 5% of the heart volume), and D10 were correlated with risk of radiation pneumonitis (P

Original languageEnglish
Pages (from-to)1114-1119
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume88
Issue number5
DOIs
Publication statusPublished - Apr 1 2014

Fingerprint

Non-Small Cell Lung Carcinoma
lungs
radiation therapy
Radiotherapy
cancer
irradiation
toxicity
Radiation Pneumonitis
dosage
grade
radiation
Actuarial Analysis
rank tests
Cardiac Volume
Survival
Hemoptysis
Kaplan-Meier Estimate
subgroups
Re-Irradiation
students

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. / Trovo, Marco; Minatel, Emilio; Durofil, Elena; Polesel, Jerry; Avanzo, Michele; Baresic, Tania; Bearz, Alessandra; Del Conte, Alessandro; Franchin, Giovanni; Gobitti, Carlo; Rumeileh, Imad Abu; Trovo, Mauro G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 88, No. 5, 01.04.2014, p. 1114-1119.

Research output: Contribution to journalArticle

Trovo, Marco ; Minatel, Emilio ; Durofil, Elena ; Polesel, Jerry ; Avanzo, Michele ; Baresic, Tania ; Bearz, Alessandra ; Del Conte, Alessandro ; Franchin, Giovanni ; Gobitti, Carlo ; Rumeileh, Imad Abu ; Trovo, Mauro G. / Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer. In: International Journal of Radiation Oncology Biology Physics. 2014 ; Vol. 88, No. 5. pp. 1114-1119.
@article{442b787d5b6a4017bc31f4b6545098af,
title = "Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer",
abstract = "Purpose To retrospectively assess toxicity and outcome of re-irradiation with stereotactic body radiation therapy (SBRT) in patients with recurrent or persistent non-small cell lung cancer (NSCLC), who were previously treated with radical radiation therapy (50-60 Gy). The secondary endpoint was to investigate whether there are dosimetric parameter predictors of severe radiation toxicity. Methods and Materials The analysis was conducted in 17 patients with {"}in-field{"} recurrent/persistent centrally located NSCLC, who underwent re-irradiation with SBRT. SBRT consisted of 30 Gy in 5 to 6 fractions; these prescriptions would be equivalent for the tumor to 37.5 to 40 Gy, bringing the total 2-Gy-per-fraction cumulative dose to 87 to 100 Gy, considering the primary radiation therapy treatment. Actuarial analyses and survival were calculated by the Kaplan-Meier method, and P values were estimated by the log-rank test, starting from the date of completion of SBRT. Dosimetric parameters from the subgroups with and without grade ≥3 pulmonary toxicity were compared using a 2-tailed Student t test. Results The median follow-up was 18 months (range, 4-57 months). Only 2 patients had local failure, corresponding to a local control rate of 86{\%} at 1 year. The Kaplan-Meier estimates of overall survival (OS) rates at 1 and 2 years were 59{\%} and 29{\%}, respectively; the median OS was 19 months. Four patients (23{\%}) experienced grade 3 radiation pneumonitis, and 1 patient developed fatal pneumonitis. One patient died of fatal hemoptysis 2 months after the completion of SBRT. Unexpectedly, heart maximum dose, D5 (minimum dose to at least 5{\%} of the heart volume), and D10 were correlated with risk of radiation pneumonitis (P",
author = "Marco Trovo and Emilio Minatel and Elena Durofil and Jerry Polesel and Michele Avanzo and Tania Baresic and Alessandra Bearz and {Del Conte}, Alessandro and Giovanni Franchin and Carlo Gobitti and Rumeileh, {Imad Abu} and Trovo, {Mauro G.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1016/j.ijrobp.2014.01.012",
language = "English",
volume = "88",
pages = "1114--1119",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for re-irradiation of persistent or recurrent non-small cell lung cancer

AU - Trovo, Marco

AU - Minatel, Emilio

AU - Durofil, Elena

AU - Polesel, Jerry

AU - Avanzo, Michele

AU - Baresic, Tania

AU - Bearz, Alessandra

AU - Del Conte, Alessandro

AU - Franchin, Giovanni

AU - Gobitti, Carlo

AU - Rumeileh, Imad Abu

AU - Trovo, Mauro G.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Purpose To retrospectively assess toxicity and outcome of re-irradiation with stereotactic body radiation therapy (SBRT) in patients with recurrent or persistent non-small cell lung cancer (NSCLC), who were previously treated with radical radiation therapy (50-60 Gy). The secondary endpoint was to investigate whether there are dosimetric parameter predictors of severe radiation toxicity. Methods and Materials The analysis was conducted in 17 patients with "in-field" recurrent/persistent centrally located NSCLC, who underwent re-irradiation with SBRT. SBRT consisted of 30 Gy in 5 to 6 fractions; these prescriptions would be equivalent for the tumor to 37.5 to 40 Gy, bringing the total 2-Gy-per-fraction cumulative dose to 87 to 100 Gy, considering the primary radiation therapy treatment. Actuarial analyses and survival were calculated by the Kaplan-Meier method, and P values were estimated by the log-rank test, starting from the date of completion of SBRT. Dosimetric parameters from the subgroups with and without grade ≥3 pulmonary toxicity were compared using a 2-tailed Student t test. Results The median follow-up was 18 months (range, 4-57 months). Only 2 patients had local failure, corresponding to a local control rate of 86% at 1 year. The Kaplan-Meier estimates of overall survival (OS) rates at 1 and 2 years were 59% and 29%, respectively; the median OS was 19 months. Four patients (23%) experienced grade 3 radiation pneumonitis, and 1 patient developed fatal pneumonitis. One patient died of fatal hemoptysis 2 months after the completion of SBRT. Unexpectedly, heart maximum dose, D5 (minimum dose to at least 5% of the heart volume), and D10 were correlated with risk of radiation pneumonitis (P

AB - Purpose To retrospectively assess toxicity and outcome of re-irradiation with stereotactic body radiation therapy (SBRT) in patients with recurrent or persistent non-small cell lung cancer (NSCLC), who were previously treated with radical radiation therapy (50-60 Gy). The secondary endpoint was to investigate whether there are dosimetric parameter predictors of severe radiation toxicity. Methods and Materials The analysis was conducted in 17 patients with "in-field" recurrent/persistent centrally located NSCLC, who underwent re-irradiation with SBRT. SBRT consisted of 30 Gy in 5 to 6 fractions; these prescriptions would be equivalent for the tumor to 37.5 to 40 Gy, bringing the total 2-Gy-per-fraction cumulative dose to 87 to 100 Gy, considering the primary radiation therapy treatment. Actuarial analyses and survival were calculated by the Kaplan-Meier method, and P values were estimated by the log-rank test, starting from the date of completion of SBRT. Dosimetric parameters from the subgroups with and without grade ≥3 pulmonary toxicity were compared using a 2-tailed Student t test. Results The median follow-up was 18 months (range, 4-57 months). Only 2 patients had local failure, corresponding to a local control rate of 86% at 1 year. The Kaplan-Meier estimates of overall survival (OS) rates at 1 and 2 years were 59% and 29%, respectively; the median OS was 19 months. Four patients (23%) experienced grade 3 radiation pneumonitis, and 1 patient developed fatal pneumonitis. One patient died of fatal hemoptysis 2 months after the completion of SBRT. Unexpectedly, heart maximum dose, D5 (minimum dose to at least 5% of the heart volume), and D10 were correlated with risk of radiation pneumonitis (P

UR - http://www.scopus.com/inward/record.url?scp=84897911455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897911455&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2014.01.012

DO - 10.1016/j.ijrobp.2014.01.012

M3 - Article

C2 - 24661664

AN - SCOPUS:84897911455

VL - 88

SP - 1114

EP - 1119

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 5

ER -